Ancora Advisors LLC increased its stake in Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 160.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,067,867 shares of the biopharmaceutical company's stock after acquiring an additional 658,600 shares during the period. Ancora Advisors LLC owned approximately 2.08% of Emergent Biosolutions worth $8,949,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Millennium Management LLC boosted its holdings in shares of Emergent Biosolutions by 68.9% in the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company's stock valued at $12,162,000 after purchasing an additional 1,020,582 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Emergent Biosolutions by 12.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company's stock worth $5,301,000 after buying an additional 121,583 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Emergent Biosolutions during the 2nd quarter worth $31,000. Rhumbline Advisers raised its position in shares of Emergent Biosolutions by 862.4% in the 2nd quarter. Rhumbline Advisers now owns 84,025 shares of the biopharmaceutical company's stock worth $536,000 after buying an additional 75,294 shares during the period. Finally, Jump Financial LLC purchased a new position in shares of Emergent Biosolutions in the 2nd quarter worth $352,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on EBS shares. UBS Group reaffirmed a "buy" rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Weiss Ratings upgraded shares of Emergent Biosolutions from a "sell (d-)" rating to a "sell (d)" rating in a report on Friday, August 21st. Benchmark reaffirmed a "buy" rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. HC Wainwright decreased their price objective on shares of Emergent Biosolutions from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, August 10th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Emergent Biosolutions in a research report on Friday, August 21st. They issued an "underweight" rating for the company. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $10.00.
Read Our Latest Analysis on Emergent Biosolutions
Emergent Biosolutions Stock Up 1.1%
Shares of NYSE:EBS opened at $6.17 on Wednesday. The company has a market capitalization of $316.34 million, a price-to-earnings ratio of -1.74 and a beta of 2.34. The company has a 50 day moving average of $6.81 and a two-hundred day moving average of $7.99. Emergent Biosolutions Inc. has a 52-week low of $4.36 and a 52-week high of $14.06. The company has a quick ratio of 2.95, a current ratio of 5.42 and a debt-to-equity ratio of 1.70.
Emergent Biosolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.68. The firm had revenue of $234.30 million for the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. As a group, analysts forecast that Emergent Biosolutions Inc. will post -4.61 earnings per share for the current fiscal year.
Insider Activity
In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total transaction of $25,200.00. Following the transaction, the senior vice president owned 159,098 shares of the company's stock, valued at $1,336,423.20. This trade represents a 1.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.00% of the company's stock.
About Emergent Biosolutions
(
Free Report)
Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.
Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.
Featured Articles
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc. (NYSE:EBS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Emergent Biosolutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emergent Biosolutions wasn't on the list.
While Emergent Biosolutions currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
